Cargando…
Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
CONTEXT: Thyroid eye disease (TED) is a sight-threatening and debilitating autoimmune condition, with limited therapies available, that often poses diagnostic and therapeutic challenges. In recent years, the treatment landscape has shifted to early intervention with targeted therapy. METHODS: A PubM...
Autores principales: | Kossler, Andrea Lora, Douglas, Raymond, Dosiou, Chrysoula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359446/ https://www.ncbi.nlm.nih.gov/pubmed/36346685 http://dx.doi.org/10.1210/clinem/dgac168 |
Ejemplares similares
-
Thyroid Eye Disease: Navigating the New Treatment Landscape
por: Dosiou, Chrysoula, et al.
Publicado: (2021) -
Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021) -
Teprotumumab for the treatment of chronic thyroid eye disease
por: Ugradar, Shoaib, et al.
Publicado: (2021) -
RF35 | PSAT299 Thyroid Eye Disease Activation After mRNA SARS-CoV-2 Vaccination in Patients With Autoimmune Thyroid Disease
por: Mohamed, Abubakr, et al.
Publicado: (2022) -
Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report
por: Lu, Tracy J., et al.
Publicado: (2023)